Published in Antimicrob Agents Chemother on March 29, 2010
A West Nile virus DNA vaccine utilizing a modified promoter induces neutralizing antibody in younger and older healthy adults in a phase I clinical trial. J Infect Dis (2011) 1.42
Clinical manifestations and outcomes of West Nile virus infection. Viruses (2014) 1.05
Experimental therapies for yellow fever. Antiviral Res (2012) 0.96
West Nile virus: A re-emerging pathogen revisited. World J Virol (2012) 0.94
Novel approaches and challenges to treatment of central nervous system viral infections. Ann Neurol (2013) 0.90
Antibody-Based Strategies to Prevent and Treat Influenza. Front Immunol (2015) 0.88
Potent dengue virus neutralization by a therapeutic antibody with low monovalent affinity requires bivalent engagement. PLoS Pathog (2014) 0.86
Treatment of mice with human monoclonal antibody 24h after lethal aerosol challenge with virulent Venezuelan equine encephalitis virus prevents disease but not infection. Virology (2011) 0.85
Giving monoclonal antibodies to healthy volunteers in phase 1 trials: is it safe? Br J Clin Pharmacol (2013) 0.84
Treatment of spatial memory impairment in hamsters infected with West Nile virus using a humanized monoclonal antibody MGAWN1. Antiviral Res (2011) 0.83
A humanized IgG but not IgM antibody is effective in prophylaxis and therapy of yellow fever infection in an AG129/17D-204 peripheral challenge mouse model. Antiviral Res (2012) 0.83
West nile virus. Transfus Med Hemother (2013) 0.81
Possible future monoclonal antibody (mAb)-based therapy against arbovirus infections. Biomed Res Int (2013) 0.80
Risk factors for West Nile virus infection and disease in populations and individuals. Expert Rev Anti Infect Ther (2015) 0.79
Impact of viral attachment factor expression on antibody-mediated neutralization of flaviviruses. Virology (2013) 0.76
Determination of the starting dose in the first-in-human clinical trials with monoclonal antibodies: a systematic review of papers published between 1990 and 2013. Drug Des Devel Ther (2016) 0.75
A humanized monoclonal antibody neutralizes yellow fever virus strain 17D-204 in vitro but does not protect a mouse model from disease. Antiviral Res (2016) 0.75
Epidemic West Nile encephalitis, New York, 1999: results of a household-based seroepidemiological survey. Lancet (2001) 6.49
Development of a humanized monoclonal antibody with therapeutic potential against West Nile virus. Nat Med (2005) 5.09
West Nile virus: a primer for the clinician. Ann Intern Med (2002) 4.81
Structural basis of West Nile virus neutralization by a therapeutic antibody. Nature (2005) 3.51
The epidemic of West Nile virus in the United States, 2002. Vector Borne Zoonotic Dis (2004) 2.86
West Nile virus neuroinvasive disease. Ann Neurol (2006) 2.42
Trastuzumab in CSF. J Clin Oncol (2000) 2.35
Rituximab therapy for CNS lymphomas: targeting the leptomeningeal compartment. Blood (2002) 2.28
Humanized monoclonal antibody against West Nile virus envelope protein administered after neuronal infection protects against lethal encephalitis in hamsters. J Infect Dis (2006) 1.84
Recommendations on risk-based strategies for detection and characterization of antibodies against biotechnology products. J Immunol Methods (2008) 1.60
A phase 1 study of PAmAb, a fully human monoclonal antibody against Bacillus anthracis protective antigen, in healthy volunteers. Clin Infect Dis (2005) 1.47
Manifestations of West Nile neuroinvasive disease. Rev Med Virol (2006) 1.45
A therapeutic antibody against west nile virus neutralizes infection by blocking fusion within endosomes. PLoS Pathog (2009) 1.41
Defining limits of treatment with humanized neutralizing monoclonal antibody for West Nile virus neurological infection in a hamster model. Antimicrob Agents Chemother (2007) 1.30
Intraventricular treatment of relapsed central nervous system lymphoma with the anti-CD20 antibody rituximab. Haematologica (2004) 1.23
Phase 1 evaluation of the respiratory syncytial virus-specific monoclonal antibody palivizumab in recipients of hematopoietic stem cell transplants. J Infect Dis (2001) 1.16
Human immunoglobulin as a treatment for West Nile virus infection. J Infect Dis (2003) 1.13
Safety and pharmacokinetics of palivizumab therapy in children hospitalized with respiratory syncytial virus infection. Pediatr Infect Dis J (2004) 1.11
Safety, tolerability, pharmacokinetics, and immunogenicity of motavizumab, a humanized, enhanced-potency monoclonal antibody for the prevention of respiratory syncytial virus infection in at-risk children. Pediatr Infect Dis J (2009) 1.08
Complement activation in circulation and central nervous system after rituximab (anti-CD20) treatment of B-cell lymphoma. Leuk Lymphoma (2001) 1.02
West Nile virus-induced acute flaccid paralysis is prevented by monoclonal antibody treatment when administered after infection of spinal cord neurons. J Neurovirol (2008) 1.01
Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I. Arthritis Rheum (2008) 13.08
Obesity-associated improvements in metabolic profile through expansion of adipose tissue. J Clin Invest (2007) 8.71
Development of a humanized monoclonal antibody with therapeutic potential against West Nile virus. Nat Med (2005) 5.09
Teplizumab for treatment of type 1 diabetes (Protégé study): 1-year results from a randomised, placebo-controlled trial. Lancet (2011) 4.15
Detection of functional haematopoietic stem cell niche using real-time imaging. Nature (2008) 4.06
Risk of suicidality in clinical trials of antidepressants in adults: analysis of proprietary data submitted to US Food and Drug Administration. BMJ (2009) 3.97
Structural basis of West Nile virus neutralization by a therapeutic antibody. Nature (2005) 3.51
Breast tumor copy number aberration phenotypes and genomic instability. BMC Cancer (2006) 3.34
Lethal antibody enhancement of dengue disease in mice is prevented by Fc modification. PLoS Pathog (2010) 3.16
Desmosomal dysfunction due to mutations in desmoplakin causes arrhythmogenic right ventricular dysplasia/cardiomyopathy. Circ Res (2006) 2.95
MicroRNA-31 functions as an oncogenic microRNA in mouse and human lung cancer cells by repressing specific tumor suppressors. J Clin Invest (2010) 2.87
Genome sequence of foxtail millet (Setaria italica) provides insights into grass evolution and biofuel potential. Nat Biotechnol (2012) 2.82
Solution NMR studies of the A beta(1-40) and A beta(1-42) peptides establish that the Met35 oxidation state affects the mechanism of amyloid formation. J Am Chem Soc (2004) 2.79
AP-3 directs the intracellular trafficking of HIV-1 Gag and plays a key role in particle assembly. Cell (2005) 2.68
Set2 methylation of histone H3 lysine 36 suppresses histone exchange on transcribed genes. Nature (2012) 2.57
Development of motavizumab, an ultra-potent antibody for the prevention of respiratory syncytial virus infection in the upper and lower respiratory tract. J Mol Biol (2007) 2.45
Chromatin remodelers Isw1 and Chd1 maintain chromatin structure during transcription by preventing histone exchange. Nat Struct Mol Biol (2012) 2.37
microRNA-21 negatively regulates Cdc25A and cell cycle progression in colon cancer cells. Cancer Res (2009) 2.32
Frequent mutation of the PI3K pathway in head and neck cancer defines predictive biomarkers. Cancer Discov (2013) 2.29
Selective blockade of inhibitory Fcgamma receptor enables human dendritic cell maturation with IL-12p70 production and immunity to antibody-coated tumor cells. Proc Natl Acad Sci U S A (2005) 2.22
Maternal imprinting at the H19-Igf2 locus maintains adult haematopoietic stem cell quiescence. Nature (2013) 2.22
Uncovering growth-suppressive MicroRNAs in lung cancer. Clin Cancer Res (2009) 2.19
Genetic and biophysical basis of sudden unexplained nocturnal death syndrome (SUNDS), a disease allelic to Brugada syndrome. Hum Mol Genet (2002) 2.16
Structure and function analysis of therapeutic monoclonal antibodies against dengue virus type 2. J Virol (2010) 2.14
Risk factors for positive minor salivary gland biopsy findings in Sjögren's syndrome and dry mouth patients. Arthritis Rheum (2002) 2.10
Generating daily high spatial land surface temperatures by combining ASTER and MODIS land surface temperature products for environmental process monitoring. Environ Sci Process Impacts (2015) 2.03
The development of therapeutic antibodies that neutralize homologous and heterologous genotypes of dengue virus type 1. PLoS Pathog (2010) 2.03
Structural insights on the Mycobacterium tuberculosis proteasomal ATPase Mpa. Structure (2009) 1.96
Application of dual affinity retargeting molecules to achieve optimal redirected T-cell killing of B-cell lymphoma. Blood (2011) 1.95
Nebulette mutations are associated with dilated cardiomyopathy and endocardial fibroelastosis. J Am Coll Cardiol (2010) 1.88
Humanized monoclonal antibody against West Nile virus envelope protein administered after neuronal infection protects against lethal encephalitis in hamsters. J Infect Dis (2006) 1.84
Selective dysregulation of the FcgammaIIB receptor on memory B cells in SLE. J Exp Med (2006) 1.81
Augmented interferon-alpha pathway activation in patients with Sjögren's syndrome treated with etanercept. Arthritis Rheum (2007) 1.80
Delayed correlation of mRNA and protein expression in rapamycin-treated cells and a role for Ggc1 in cellular sensitivity to rapamycin. Mol Cell Proteomics (2009) 1.76
Cryoelectron microscopy structure of purified gamma-secretase at 12 A resolution. J Mol Biol (2008) 1.75
Structural insight into the ion-exchange mechanism of the sodium/calcium exchanger. Science (2012) 1.74
Suppression of nucleotide metabolism underlies the establishment and maintenance of oncogene-induced senescence. Cell Rep (2013) 1.74
Bone proteins PHEX and DMP1 regulate fibroblastic growth factor Fgf23 expression in osteocytes through a common pathway involving FGF receptor (FGFR) signaling. FASEB J (2011) 1.74
Crystal structure of the Caenorhabditis elegans apoptosome reveals an octameric assembly of CED-4. Cell (2010) 1.73
Mutations in PDLIM3 and MYOZ1 encoding myocyte Z line proteins are infrequently found in idiopathic dilated cardiomyopathy. Mol Genet Metab (2007) 1.60
Phosphatidylinositol monophosphate-binding interface in the oomycete RXLR effector AVR3a is required for its stability in host cells to modulate plant immunity. Proc Natl Acad Sci U S A (2011) 1.59
Genotype-specific neutralization and protection by antibodies against dengue virus type 3. J Virol (2010) 1.58
ERG oncogene modulates prostaglandin signaling in prostate cancer cells. Cancer Biol Ther (2011) 1.56
A placebo- and midazolam-controlled phase I single ascending-dose study evaluating the safety, pharmacokinetics, and pharmacodynamics of remimazolam (CNS 7056): Part I. Safety, efficacy, and basic pharmacokinetics. Anesth Analg (2011) 1.56
Differentiation of human bone marrow-derived cells into buccal epithelial cells in vivo: a molecular analytical study. Lancet (2003) 1.56
Memory B cells, but not long-lived plasma cells, possess antigen specificities for viral escape mutants. J Exp Med (2011) 1.53
Fc optimization of therapeutic antibodies enhances their ability to kill tumor cells in vitro and controls tumor expansion in vivo via low-affinity activating Fcgamma receptors. Cancer Res (2007) 1.48
Development of a highly protective combination monoclonal antibody therapy against Chikungunya virus. PLoS Pathog (2013) 1.47
Automatic selection of tube potential for radiation dose reduction in CT: a general strategy. Med Phys (2010) 1.46
Integrative genomic analyses of neurofibromatosis tumours identify SOX9 as a biomarker and survival gene. EMBO Mol Med (2009) 1.41
Two microtubule-associated proteins of the Arabidopsis MAP65 family function differently on microtubules. Plant Physiol (2005) 1.37
Complement protein C1q inhibits antibody-dependent enhancement of flavivirus infection in an IgG subclass-specific manner. Cell Host Microbe (2007) 1.37
mTORC2 is required for proliferation and survival of TSC2-null cells. Mol Cell Biol (2011) 1.36
Etanercept in Sjögren's syndrome: a twelve-week randomized, double-blind, placebo-controlled pilot clinical trial. Arthritis Rheum (2004) 1.36
N-terminus of M2 protein could induce antibodies with inhibitory activity against influenza virus replication. FEMS Immunol Med Microbiol (2003) 1.35
Novel regulators of Fgf23 expression and mineralization in Hyp bone. Mol Endocrinol (2009) 1.34
Induction of p21-dependent senescence by an NAE inhibitor, MLN4924, as a mechanism of growth suppression. Neoplasia (2011) 1.34
In vivo and in vitro peripheral-type benzodiazepine receptor polymerization: functional significance in drug ligand and cholesterol binding. Biochemistry (2003) 1.34
Multiple polyadenylated RNA viruses detected in pooled cultivated and wild plant samples. Arch Virol (2011) 1.33
A scoring model based on neutrophil to lymphocyte ratio predicts recurrence of HBV-associated hepatocellular carcinoma after liver transplantation. PLoS One (2011) 1.32
Characteristics of adolescent females in juvenile detention. Int J Law Psychiatry (2004) 1.32
Cytoglobin overexpression protects against damage-induced fibrosis. Mol Ther (2006) 1.32
Effects of the neurokinin1 receptor antagonist aprepitant on the pharmacokinetics of dexamethasone and methylprednisolone. Clin Pharmacol Ther (2003) 1.31
Structural basis of differential neutralization of DENV-1 genotypes by an antibody that recognizes a cryptic epitope. PLoS Pathog (2012) 1.31
Radiosensitization of human pancreatic cancer cells by MLN4924, an investigational NEDD8-activating enzyme inhibitor. Cancer Res (2011) 1.31
Defining limits of treatment with humanized neutralizing monoclonal antibody for West Nile virus neurological infection in a hamster model. Antimicrob Agents Chemother (2007) 1.30
A fast inverse consistent deformable image registration method based on symmetric optical flow computation. Phys Med Biol (2008) 1.29
Angiostrongyliasis, Mainland China. Emerg Infect Dis (2005) 1.29
Wnt5a suppresses epithelial ovarian cancer by promoting cellular senescence. Cancer Res (2011) 1.29
Local adeno-associated virus-mediated interleukin 10 gene transfer has disease-modifying effects in a murine model of Sjögren's syndrome. Hum Gene Ther (2003) 1.28
Complement protein C1q reduces the stoichiometric threshold for antibody-mediated neutralization of West Nile virus. Cell Host Microbe (2009) 1.27
Xerostomia and the geriatric patient. J Am Geriatr Soc (2002) 1.26
Locally disordered conformer of the hamster prion protein: a crucial intermediate to PrPSc? Biochemistry (2002) 1.24
Capturing a flavivirus pre-fusion intermediate. PLoS Pathog (2009) 1.24
Monoclonal antibody produced in plants efficiently treats West Nile virus infection in mice. Proc Natl Acad Sci U S A (2010) 1.23
MicroRNA-10b regulates tumorigenesis in neurofibromatosis type 1. Cancer Sci (2010) 1.23
Agricultural productivity changes induced by the sloping land conversion program: an analysis of Wuqi county in the Loess Plateau region. Environ Manage (2009) 1.22
Functional analysis of antibodies against dengue virus type 4 reveals strain-dependent epitope exposure that impacts neutralization and protection. J Virol (2013) 1.22
Can transanal tube placement after anterior resection for rectal carcinoma reduce anastomotic leakage rate? A single-institution prospective randomized study. World J Surg (2011) 1.22
Flavour compounds in tomato fruits: identification of loci and potential pathways affecting volatile composition. J Exp Bot (2008) 1.20
A comparative transcriptome analysis identifying FGF23 regulated genes in the kidney of a mouse CKD model. PLoS One (2012) 1.20
Therapeutic efficacy of antibodies lacking Fcγ receptor binding against lethal dengue virus infection is due to neutralizing potency and blocking of enhancing antibodies [corrected]. PLoS Pathog (2013) 1.20
Efficacy and safety of levomilnacipran sustained release in moderate to severe major depressive disorder: a randomized, double-blind, placebo-controlled, proof-of-concept study. J Clin Psychiatry (2013) 1.19
Teplizumab preserves C-peptide in recent-onset type 1 diabetes: two-year results from the randomized, placebo-controlled Protégé trial. Diabetes (2013) 1.19
Effect of matrine on HeLa cell adhesion and migration. Eur J Pharmacol (2007) 1.19
FASL -844C polymorphism is associated with increased activation-induced T cell death and risk of cervical cancer. J Exp Med (2005) 1.19
Cohesin proteins promote ribosomal RNA production and protein translation in yeast and human cells. PLoS Genet (2012) 1.17
Differential expression patterns of the hox gene are associated with differential growth of insect hind legs. Proc Natl Acad Sci U S A (2004) 1.17